SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, today announced the publication of an article in Nature Biotechnology (Crooke, S.T., et al. Nature Biotechnology advanced online ...

SAN DIEGO, April 15, 2025--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, is celebrating five years of success in establishing a unique non-profit model bringing personalized experimental ASO ...

SAN DIEGO, Calif.--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, celebrates two years of progress in pioneering a novel non-profit approach to providing personalized experimental antisense ...

SAN DIEGO, Jan. 26, 2021 /PRNewswire/ -- n-Lorem Foundation, the first and only nonprofit organization whose mission is to create experimental antisense oligonucleotide (ASO) treatments for patients ...

n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for patients living with genetic diseases, today ...

n-Lorem, a nonprofit foundation, announced today that it will hold its third annual Nano-rare Patient Colloquium in Cambridge, Mass., where n-Lorem leaders and experts in the field will share updates ...

Retirement typically means more time for traveling, hobbies, and relaxation. For Stan Crooke, MD, PhD, it means something very different. Crooke, the founder and executive chairman of Ionis ...

Foundation’s collaboration with premier rare disease company strengthens efforts to reach more patients in need n-Lorem Foundation is the first and only foundation with a mission to provide ...

SAN DIEGO and GENEVA, Jan. 13, 2026 /PRNewswire/ -- The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to n-Lorem's antisense ...

Collaboration provides GondolaBio access to n-Lorem’s AI-informed, world-class ASO capabilities to discover novel ASO medicines for patients in need GondolaBio is a clinical-stage biotechnology ...